Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-78306358 |
Synonyms | |
Therapy Description |
JNJ-78306358 is a bispecific antibody that targets HLA-G expressed on tumor cells and the T-lymphocyte antigen CD3, potentially leading to activation of a cytotoxic T-lymphocyte response against tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-78306358 | JNJ 78306358|JNJ78306358 | CD3 Antibody 99 | JNJ-78306358 is a bispecific antibody that targets HLA-G expressed on tumor cells and the T-lymphocyte antigen CD3, potentially leading to activation of a cytotoxic T-lymphocyte response against tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04991740 | Phase I | JNJ-78306358 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Completed | ISR | ESP | 0 |